Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Aravantinos, G.; Pectasides, Dimitrios

doi:10.1186/1757-2215-7-57

Cited by 57 publications

(45 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One strategy designed to improve patient outcomes involves combining targeted agents, which possess distinct mechanisms of action and favorable tolerability, with established chemotherapeutics [26]. Validation of this approach is exemplified by the approval of bevacizumab for use alongside paclitaxel, PLD or topotecan in platinum-resistant, recurrent disease [27,28]. Furthermore, the approval of bevacizumab, olaparib and niraparib as maintenance therapy underscores the degree to which targeted agents are presently impacting the treatment landscape for patients with advanced ovarian cancer.…”

Section: Ovarian Cancer Landscapementioning

confidence: 99%

A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer

et al. 2017

View full text Add to dashboard Cite

Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality among women. Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-α, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease. Ongoing Phase III monotherapy and Phase Ib/II combination trials evaluating its activity in the setting of platinum resistance are emphasized, which will help define its role in the evolving landscape of ovarian cancer therapy. Ovarian cancer landscapeOvarian cancer remains a leading cause of gynecological cancer mortality, responsible for 152,000 deaths annually worldwide [1]. In the USA alone, it is estimated that 22,440 women will be diagnosed with ovarian cancer in 2017 and more than 14,000 will die due to this disease [2]. The remarkable degree of cellular and molecular heterogeneity exhibited by tumors of the ovary (including those arising from the fallopian tubes and primary peritoneum) is such that ovarian cancer is no longer considered a single disease entity with variable morphology, but rather a collection of neoplasms each associated with their own distinct histological subtypes and response to therapy [3,4]. Among these, epithelial ovarian cancer (EOC) accounts for approximately 95% of ovarian cancer malignancies [5,6]. The foundation of current standard-of-care treatment for women diagnosed with EOC is cytoreductive (debulking) surgery and chemotherapy using a platinum-based combination regimen, most commonly the carboplatin-paclitaxel doublet. This strategy has largely reached a plateau of effectiveness in improving overall patient survival [7,8]. The continuing high mortality is associated, at least in part, with the fact that EOC is overwhelmingly diagnosed at an advanced stage. Furthermore, while EOC is highly chemosensitive and most individuals achieve remission with front-line therapy, up to 80% of patients relapse and require further treatment without the expectation of cure [9].The development of platinum resistance in EOC appears to be a dynamic and multifactorial process, although the underlying molecular mechanisms remain poorly defined [10,11]. Recurrent EOC is classified based on the length Drug Evaluation Moore, Martin, O'Malley et al. of time, empirically divided into 6-month blocks, since receiving treatment with a platinum agent, known as the platinum-free interval [7,12]. The classification is as follows:r Refractory: progression during or within 4 weeks of platinum-based chemotherapy; r Primary resistant: relapse within 6 months of completing initial platinum therapy; r Partially platinum sensitive: relapse between 6 and 12 months; r Platinum sensitiv...

show abstract

Section: Ovarian Cancer Landscapementioning

confidence: 99%

A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…24 Bevacizumab, an antibody against VEGF, has shown efficacy when added to standard chemotherapy in 4 randomized phase III trials of patients with ovarian cancer. 25 Bevacizumab may also elicit a tumor response in patients with chemotherapy-refractory ovarian cancer when given as monotherapy. 26 Several small-molecule tyrosine kinase inhibitors that target VEGF receptors have been investigated in phase III trials for ovarian cancer treatment as either maintenance treatment after first-line chemotherapy, for example, pazopanib and nintedanib, or in relapsed ovarian cancer, for example, cediranib, with positive PFS results (for cediranib, also with positive OS results), although none of them have yet been approved for clinical use.…”

mentioning

confidence: 99%

The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Boisen

Madsen²,

Dehlendorff³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, evidence suggests that overall survival has improved because of the availability of multiple antineoplastic agents, such as gemcitabine (Gemzar ® ), liposomal doxorubicin (Doxil ® ), and topotecan (Hycamtin ® ) (Markman, 2013). The use of monoclonal antibodies is being explored with treatment options specific to the BRCA gene mutation (Aravantinos & Pectasides, 2014; Gallagher et al, 2011). When surgery is performed by a gynecologic oncologist rather than a general gynecologist, patients have an additional six to nine months survival benefit; general surgeons often perform a less aggressive surgery (Fader & Rose, 2007).…”

Section: Epithelial Ovarian Cancer and Treatmentmentioning

confidence: 99%

Caregiver Burden in End-Stage Ovarian Cancer

Hartnett¹,

Thom²,

Kline³

2016

CJON

View full text Add to dashboard Cite

Background Caregiver burden associated with caring for women with ovarian cancer has received limited focus. However, these patients often have complex needs, requiring a high level of care at home and imposing substantial burdens on caregivers. Objectives This pilot study assessed the level of caregiver burden experienced by the primary caregivers of patients with end-stage ovarian cancer and identified variables associated with caregiver burden. Methods Caregiver burden was assessed using the Caregiver Reaction Assessment. Fifty caregivers completed an anonymous and voluntary survey. Pearson correlations and independent samples t tests were used to analyze data. Findings Most participants were Caucasian, married or living with a partner, and college graduates, with an annual household income of less than $90,000. Caregiver ages ranged from 29–81 years. Participants agreed most with the self-esteem scale, indicating they had pride in caring for their loved ones. Disrupted schedules and financial problems were the most burdensome factors in providing care. Because financial issues affected caregiver burden, nurses should facilitate interdisciplinary support. Future research is needed to determine the impact of nurse-led interventions to reduce caregiver burden.

show abstract

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Cited by 57 publications

References 54 publications

A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer

A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer

The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Caregiver Burden in End-Stage Ovarian Cancer

Contact Info

Product

Resources

About